Bruker BioSpin expands its offering in tube-based sample changers with the introduction of SampleJet, a versatile, high-end robotics system that suits both high-throughput NMR and walk-up operations
SampleJet uses state-of-the-art robotics technology to rapidly transfer NMR sample tubes arranged in 96-sample format racks into the NMR spectrometer.
The SampleJet complements Bruker BioSpin's full range of NMR sample handling systems, including tubebased and flow-injection automation.
The SampleJet blends seamlessly into modern NMR laboratory automation.
It has capacity for up to 480 sample tubes, which are arranged in five separate 96-sample format racks, which are compatible with automated sample preparation and allow handling of commonly used 5mm and 1mm sample tubes.
For individual sample analysis, the SampleJet accepts single tube samples via a separate carousel that can hold up to 47 tubes.
The SampleJet was designed and developed in close collaboration with customers in the pharmaceutical and chemical industries addressing their need for fast turnover of large amounts of NMR samples together with routine walk-up capabilities.
"NMR throughput is of increasing importance," commented Till Kuehn, SampleJet product manager for Bruker BioSpin.
"The new SampleJet delivers to our customers a compact solution that is specifically tailored for high-throughput laboratories, while retaining the flexibility for walk-up work".
The SampleJet installs on top of virtually any Bruker BioSpin NMR magnet in the field without the need for additional laboratory space.
It is controlled by Bruker BioSpin's automation software, IconNMR, making it easy to integrate into any laboratory.
Several SampleJets have recently been installed at customers' sites where they are used in a variety of applications including protein-ligand screening, metabolic profiling, compound depository QA and synthesis QC of products from parallel synthesis.
"The SampleJet is a tool that helped us increase our sample throughput enormously.
"It has become our workhorse without which we could not even get close to achieving the results that we are now getting in this very short time," commented Duncan Farrant of GlaxoSmithKline's Medicines Research Centre in Stevenage, UK.
